EUVIMEDEUVIMED entdecken
Open Access

SMARCAL1 is a candidate therapeutic target for ALT-positive tumors

Angelo Taglialatela, Jina Lee, Benura Azeroglu, Xiao Chen, Maria Rosaria Dello Stritto, Antoine Gouge, Tomas Lama-Diaz, Alina Vaitsiankova, Giuseppe Leuzzi, Filemon Dela Cruz, Zahra F Khan, Andrew L Kung und 4 weitere

Genes & Development · 01.08.2026 · 40 (15-16) · 1283-1303

DOI: 10.1101/gad.353377.125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes & Development, online erschienen am 14.07.2026. Verfasst von Angelo Taglialatela und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 10032, USA; at2999@cumc.co…. Hauptthemen laut MEDLINE: DNA Helicases, Telomere Homeostasis, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A significant subset of tumors, including >50% of osteosarcomas—an aggressive bone malignancy affecting children, adolescents, and young adults—relies on alternative lengthening of telomeres (ALT), a telomerase-independent, DNA repair-based mechanism for telomere elongation. The overall 5 year survival rate for osteosarcoma patients is ∼65%, underscoring the need to develop novel targeted therapies. Through the Cancer Dependency Map, we identified SMARCAL1, a DNA translocase previously shown to remodel stalled replication forks, as a top selective dependency factor in telomerase-negative tumors. Using a panel of ALT-positive and ALT-negative cancer cell lines, as well as osteosarcoma patient-derived xenograft cells, we confirmed that ALT-positive cells are uniquely sensitive to the loss of SMARCAL1, whose depletion exacerbates ALT-dependent phenotypes and telomeric DNA damage. Notably, we demonstrated that suppressing ALT abrogates their dependency on SMARCAL1. Mechanistically, we showed that SMARCAL1 loss leads to telomeric ssDNA accumulation in ALT-positive cells, dependent in part on DNA repriming mediated by the DNA primase/polymerase PRIMPOL. Moreover, SMARCAL1's ssDNA annealing activity counteracts DNA unwinding by the BLM helicase, limiting telomeric ssDNA accumulation and DNA damage in ALT-positive cells. Importantly, SMARCAL1 depletion induces senescence in ALT-positive cancer cells, rendering them susceptible to treatment with senolytic agents. Together, these findings establish SMARCAL1 as a key regulator of ALT metabolism and highlight SMARCAL1 as a promising therapeutic target for ALT-positive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA HelicasesTelomere HomeostasisOsteosarcomaBone NeoplasmsHumansAnimalsCell Line, TumorMiceTelomereDNA DamageDNA, Single-Stranded

Stichwörter der Autor:innen

ALT-positive tumorsSMARCAL1alternative lengthening of telomerescancer dependency mapfork remodelingosteosarcomaprecision oncologyreplication stresstelomere replication

Substanzen

SMARCAL1 protein, humanDNA HelicasesDNA, Single-Stranded

Autor:innen und Institutionen

  • Department of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 10032, USA; at2999@cumc.columbia.edu ac3685@cumc.columbia.edu.
  • Institute for Cancer Genetics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 10032, USA.
  • National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20894, USA.
  • Marine College, Shandong University, Weihai 264209, China.
  • Institute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Bellinzona 6500, Switzerland.
  • Department of Genetics and Development, Columbia University Vagelos College of Physicians and Surgeons, New York, New York 10032, USA.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • Intramural NIH HHS
  • National Institutes of Health
  • NIH National Cancer Institute and Center for Cancer Research
  • Swiss Cancer Research

Zitieren

APA

Taglialatela, A., Lee, J., Azeroglu, B., Chen, X., Dello Stritto, M. R., Gouge, A., Lama-Diaz, T., Vaitsiankova, A., Leuzzi, G., Dela Cruz, F., Khan, Z. F., Kung, A. L., Cejka, P., Lazzerini Denchi, E., Min, J., & Ciccia, A. (2026). SMARCAL1 is a candidate therapeutic target for ALT-positive tumors. Genes & Development, 40(15-16), 1283-1303. https://doi.org/10.1101/gad.353377.125

Vancouver

Taglialatela A, Lee J, Azeroglu B, Chen X, Dello Stritto MR, Gouge A, et al. SMARCAL1 is a candidate therapeutic target for ALT-positive tumors. Genes & Development. 2026;40(15-16):1283-1303. doi:10.1101/gad.353377.125

BibTeX
@article{Taglialatela2026,
  author = {Taglialatela, Angelo and Lee, Jina and Azeroglu, Benura and Chen, Xiao and Dello Stritto, Maria Rosaria and Gouge, Antoine and Lama-Diaz, Tomas and Vaitsiankova, Alina and Leuzzi, Giuseppe and Dela Cruz, Filemon and Khan, Zahra F and Kung, Andrew L and Cejka, Petr and Lazzerini Denchi, Eros and Min, Jaewon and Ciccia, Alberto},
  title = {SMARCAL1 is a candidate therapeutic target for ALT-positive tumors},
  journal = {Genes & Development},
  year = {2026},
  volume = {40},
  number = {15-16},
  pages = {1283--1303},
  doi = {10.1101/gad.353377.125}
}
Kostenlos starten →